What is Leerink Partnrs' Forecast for Quanterix Q2 Earnings?

Quanterix Co. (NASDAQ:QTRX - Free Report) - Equities researchers at Leerink Partnrs lowered their Q2 2025 earnings per share estimates for shares of Quanterix in a research report issued on Monday, May 12th. Leerink Partnrs analyst P. Souda now forecasts that the company will earn ($0.45) per share for the quarter, down from their prior estimate of ($0.38). Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Quanterix's current full-year earnings is ($0.98) per share. Leerink Partnrs also issued estimates for Quanterix's Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($1.63) EPS, Q1 2026 earnings at ($0.27) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.88) EPS.

Quanterix (NASDAQ:QTRX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.69) by $0.16. The business had revenue of $30.33 million for the quarter, compared to the consensus estimate of $28.27 million. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%.

A number of other equities research analysts have also issued reports on QTRX. Leerink Partners reiterated a "market perform" rating and set a $8.00 target price (down from $12.00) on shares of Quanterix in a report on Wednesday, April 30th. Scotiabank restated an "outperform" rating on shares of Quanterix in a research report on Tuesday, March 25th. Finally, Canaccord Genuity Group dropped their price target on Quanterix from $15.00 to $12.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $15.60.

Quanterix Stock Up 3.3%

NASDAQ QTRX traded up $0.16 on Thursday, reaching $5.03. The stock had a trading volume of 283,714 shares, compared to its average volume of 797,833. The stock has a fifty day moving average price of $5.83 and a two-hundred day moving average price of $8.71. Quanterix has a 12-month low of $4.05 and a 12-month high of $19.17. The firm has a market capitalization of $195.31 million, a price-to-earnings ratio of -4.75 and a beta of 1.12.

Institutional Trading of Quanterix

Several hedge funds have recently made changes to their positions in QTRX. Resona Asset Management Co. Ltd. purchased a new position in Quanterix during the fourth quarter worth about $55,000. Tower Research Capital LLC TRC increased its position in Quanterix by 219.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock worth $61,000 after purchasing an additional 3,915 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Quanterix during the 4th quarter worth approximately $66,000. State of Wyoming acquired a new stake in shares of Quanterix in the 1st quarter valued at approximately $47,000. Finally, ProShare Advisors LLC purchased a new stake in shares of Quanterix in the fourth quarter valued at approximately $108,000. Institutional investors and hedge funds own 86.48% of the company's stock.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.